Hepatitis B Virus Reactivation in Cancer Patients Treated With Immune Checkpoint Inhibitors

There have been unique adverse events reported with targeted blockade of programmed death-1 (PD-1), programmed death-ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein-4 (CTLA4), including immune mediated toxicities. Recently, there have been reports of hepatitis B reactivation (HBVr) o...

Descripción completa

Detalles Bibliográficos
Autores principales: Burns, Ethan A., Muhsen, Ibrahim N., Anand, Kartik, Xu, Jiaqiong, Umoru, Godsfavour, Arain, Abeer N., Abdelrahim, Maen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946380/
https://www.ncbi.nlm.nih.gov/pubmed/33480637
http://dx.doi.org/10.1097/CJI.0000000000000358

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7946380/
https://www.ncbi.nlm.nih.gov/pubmed/33480637
http://dx.doi.org/10.1097/CJI.0000000000000358

Ejemplares similares